OrbiMed Advisors SIBN Position
ExitedOrbiMed Advisors exited their position in SI-BONE, Inc. (SIBN) in Q4 2025, after holding the stock for 12 quarters.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
1 other tracked fund also holds SIBN.
About SI-BONE, Inc.
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Full company profile →Short Interest
8.4%
5.9 days to cover
OrbiMed Advisors SIBN Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Exited | 0 | -2,578,979 | $0 |
| Q3 2025 | Held | 2,578,979 | — | $38.0M |
| Q2 2025 | Decreased | 2,578,979 | -863,874 | $48.5M |
| Q1 2025 | Held | 3,442,853 | — | $48.3M |
| Q4 2024 | Increased | 3,442,853 | +137,052 | $48.3M |
| Q3 2024 | Increased | 3,305,801 | +75,824 | $46.2M |
| Q2 2024 | Increased | 3,229,977 | +55,456 | $41.8M |
| Q1 2024 | Increased | 3,174,521 | +881,990 | $52.0M |
| Q4 2023 | Held | 2,292,531 | — | $48.1M |
| Q3 2023 | Held | 2,292,531 | — | $48.7M |
| Q2 2023 | Decreased | 2,292,531 | -626,923 | $61.9M |
| Q1 2023 | New | 2,919,454 | +2,919,454 | $57.4M |
Frequently Asked Questions
Does OrbiMed Advisors own SIBN?
No. OrbiMed Advisors exited their position in SI-BONE, Inc. (SIBN) in Q4 2025. They previously held the stock for 12 quarters.
How many hedge funds own SIBN?
1 specialist biotech hedge fund currently holds SIBN, including Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy SIBN?
OrbiMed Advisors's position in SIBN was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's SIBN position increasing or decreasing?
OrbiMed Advisors completely exited their SIBN position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
SIBNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →